Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30287240 | 1.00 | CYP2A6 (0.59) | CYP2A6CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL48087 | 0.84 | CYP19A1 (0.51) | CYP2A6CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL3798556 | 0.79 | CYP19A1 (0.46) | CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL506756 | 0.79 | CYP2A6 (0.57) | CYP2A6CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL2092142 | 0.79 | CYP19A1 (0.46) | CYP2A6CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL632950 | 0.77 | TDP1 (0.53) | OPRM1OPRK1 | |
| SCHEMBL13873185 | 0.77 | CYP19A1 (0.46) | CYP2A6CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL20562508 | 0.76 | CYP19A1 (0.51) | CYP2A6CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL3791450 | 0.76 | CYP19A1 (0.51) | CYP2A6CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL7800838 | 0.76 | OPRM1 (0.50) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| US-20240376097-A1 | BCL-2 Inhibitor | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-1555257-B1 | PROCESS FOR PRODUCING AROMATIC NITRILE COMPOUND | IHARA CHEMICAL IND CO (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-7262316-B2 | Process for producing aromatic nitrile compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20060069282-A1 | Process for producing aromatic nitrile compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| EP-1555257-A1 | PROCESS FOR PRODUCING AROMATIC NITRILE COMPOUND | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-4845263-A | Layered photoresponsive imaging members with sulfur incorporated dicyanomethylenefluorene carboxylate compositions of matter | XEROX CORPORATION (US) | 1989-07-04 | — | — | US | disclosed |
| US-4546059-A | Layered photoresponsive imaging members with sulfur incorporated dicyanomethylenefluorene carboxylate compositions | XEROX CORPORATION (US) | 1985-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | CYP2A6 956/4885CYP19A1 1420/4885TBXAS1 1603/4885 |
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885CYP19A1 2006/4885TBXAS1 1120/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885CYP19A1 2006/4885TBXAS1 1120/4885 |
| US-20060069282-A1 | Process for producing aromatic nitrile compound | ODC1, ALKBH3, GNMT | CYP2A6 2434/4885CYP19A1 878/4885TBXAS1 3405/4885 |
| US-20240376097-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885CYP19A1 2006/4885TBXAS1 1120/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | CYP2A6 956/4885CYP19A1 1420/4885TBXAS1 1603/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885CYP19A1 2006/4885TBXAS1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.